Exagen Inc. (NASDAQ:XGN - Free Report) - Equities researchers at B. Riley issued their Q3 2025 earnings per share estimates for Exagen in a research report issued to clients and investors on Wednesday, September 10th. B. Riley analyst A. Schock forecasts that the company will earn ($0.12) per share for the quarter. B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for Exagen's current full-year earnings is ($0.88) per share. B. Riley also issued estimates for Exagen's Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.51) EPS, Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at $0.01 EPS and FY2026 earnings at ($0.09) EPS.
Exagen (NASDAQ:XGN - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported ($0.18) EPS for the quarter, meeting analysts' consensus estimates of ($0.18). Exagen had a negative return on equity of 130.38% and a negative net margin of 28.85%.The company had revenue of $17.20 million during the quarter, compared to analyst estimates of $16.25 million. Exagen has set its FY 2025 guidance at EPS.
XGN has been the subject of several other reports. Canaccord Genuity Group raised their price objective on Exagen from $8.00 to $11.00 and gave the company a "buy" rating in a research note on Wednesday, July 30th. Craig Hallum began coverage on Exagen in a research note on Wednesday, July 23rd. They issued a "buy" rating and a $12.00 price objective for the company. KeyCorp raised Exagen from a "sector weight" rating to an "overweight" rating and set a $12.00 price objective for the company in a research note on Wednesday, July 30th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $10.00 price target on shares of Exagen in a report on Wednesday, July 30th. One investment analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. Based on data from MarketBeat.com, Exagen presently has an average rating of "Buy" and a consensus price target of $12.00.
View Our Latest Research Report on XGN
Exagen Price Performance
Shares of Exagen stock opened at $9.74 on Monday. The stock has a 50 day moving average of $8.70 and a 200 day moving average of $6.60. Exagen has a 12 month low of $2.38 and a 12 month high of $10.34. The firm has a market cap of $214.28 million, a PE ratio of -10.94 and a beta of 1.60. The company has a current ratio of 4.95, a quick ratio of 4.95 and a debt-to-equity ratio of 1.06.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC purchased a new position in Exagen during the 1st quarter worth $25,000. Northern Trust Corp increased its holdings in Exagen by 16.7% during the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company's stock worth $75,000 after purchasing an additional 2,630 shares during the period. XTX Topco Ltd purchased a new position in Exagen during the 2nd quarter worth $133,000. Occudo Quantitative Strategies LP purchased a new position in Exagen during the 2nd quarter worth $138,000. Finally, Bridgeway Capital Management LLC increased its holdings in Exagen by 10.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 27,800 shares of the company's stock worth $194,000 after purchasing an additional 2,600 shares during the period. 75.25% of the stock is currently owned by hedge funds and other institutional investors.
Exagen Company Profile
(
Get Free Report)
Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Exagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exagen wasn't on the list.
While Exagen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
